10-Q/A: Quantum Genesis AI Corp. Amends 10-Q for IP Disclosure

Quantum Genesis AI Corp. files an amendment to its Form 10-Q for the period ended January 31, 2026, to provide additional disclosure regarding intellectual property and formalize rights acquired via an asset purchase agreement.

Summary

• This filing is an amendment to Quantum Genesis AI Corp.'s Form 10-Q for the quarter ended January 31, 2026.
• The amendment specifically adds disclosure to Item 2, Management's Discussion and Analysis of Financial Condition and Results of Operations.
• The additional disclosure pertains to the company's intellectual property, including proprietary enzyme design technologies and computational methodologies.
• These intellectual properties were acquired through an Asset Purchase Agreement dated February 21, 2023.
• The filing clarifies the formalization of certain rights previously acquired, specifically concerning U.S. Patent Application Publication No. US20250146029A1, titled 'Modified Polypeptides for Enzymatic Synthesis of Ibuprofen'.
• An Assignment Agreement was entered into to formalize the transfer of intellectual property rights, effective as of November 2, 2023.
• No financial statements or other financial information in the original filing have been amended or updated.
• The company reported no revenues for the three and six months ended January 31, 2026, consistent with the prior year.
• Operating expenses decreased significantly for both the three-month and six-month periods ended January 31, 2026, compared to the prior year, attributed to reduced professional fees.
• Other expenses significantly increased due to a loss on settlement of debt during the three and six months ended January 31, 2026.
• Net losses were substantial for both periods, increasing significantly compared to the prior year, primarily driven by the loss on debt settlement.
• The company faces substantial doubt about its ability to continue as a going concern due to net losses, accumulated deficits, and cash used in operations.
• The company is dependent on external funding and has no firm agreements for future financing.
• A working capital deficit of $418,342 was reported as of January 31, 2026.
• Net cash used by operating activities was $43,810 for the six months ended January 31, 2026.
• Financing activities provided $43,285 in cash for the six months ended January 31, 2026, a decrease from the prior year due to reduced proceeds from note issuances.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to significant net losses, a going concern warning, and a lack of secured future financing, despite the positive clarification of intellectual property rights.

Positives

• Formalization of intellectual property rights, including a patent application related to enzyme design for ibuprofen synthesis, strengthens the company's asset base.
• Significant decrease in operating expenses for the three and six months ended January 31, 2026, compared to the prior year, driven by reduced professional fees.

Negatives

• The company incurred substantial net losses of $4,329,657 for the three months and $4,379,525 for the six months ended January 31, 2026.
• A significant increase in other expenses was driven by a loss on settlement of debt.
• The company has a working capital deficit of $418,342 as of January 31, 2026.
• Net cash used by operating activities was $43,810 for the six months ended January 31, 2026.
• The company faces substantial doubt about its ability to continue as a going concern due to its financial performance and cash burn.
• The company is entirely dependent on its ability to attract and receive funding from external sources, with no firm agreements in place.

Risks

• The inability to obtain sufficient funding will restrict the company's ability to grow and may require suspension of operations.
• Failure to raise additional funds will adversely affect the business and may result in a loss to stockholders.
• Any additional equity financing may involve substantial dilution to existing stockholders.
• The company's actual results and financial condition may differ materially from forward-looking statements due to inherent uncertainties and risks.
• Factors that could cause actual results to differ materially include those described in the company's Registration Statement on Form 10.

Future Outlook

The company expects operating expenses to increase in future years due to costs associated with increased operating activity under its business model. The company's ability to grow and continue operations is entirely dependent on its ability to attract and receive funding from external sources, with no firm agreements in place.

Management Comments

• The company is entirely dependent on its ability to attract and receive funding from either the sale of securities or outside sources such as private investment or a strategic partner.
• We currently have no firm agreements or arrangements with respect to any such financing and there can be no assurance that any needed funds will be available to us on acceptable terms or at all.
• The inability to obtain sufficient funding of our operations in the future will restrict our ability to grow and reduce our ability to continue to conduct business operations.
• Our failure to raise additional funds will adversely affect our business, and may require us to suspend our operations, which in turn may result in a loss to the purchasers of our common stock.
• If we are unable to obtain necessary financing, we will likely be required to curtail our development plans.
• Any additional equity financing may involve substantial dilution to our then existing stockholders.

Industry Context

StockSavvy.ai notes that Quantum Genesis AI Corp.'s amendment focuses on intellectual property, a critical asset for technology-driven companies. The clarification of IP rights, particularly those related to enzyme design for pharmaceutical synthesis, is a positive step. However, the company's significant net losses and going concern issues highlight the high-risk nature of early-stage biotechnology or AI ventures, where substantial funding is often required to advance development and commercialization, a common challenge across the industry.

Related Party Transactions

• The subject matter of U.S. Patent Application Publication No. US20250146029A1 was filed in the name of the Company's Chief Executive Officer, Naveen Krishnarao Kulkarni, prior to the formalization of IP rights transfer.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern issues and potential for dilution from future equity financing.
• Creditors may be impacted by the company's financial instability and potential inability to meet obligations.
• Employees and suppliers may be affected if operations are suspended due to a lack of funding.

Next Steps

• The company must secure external funding to continue operations and growth.
• The company may need to curtail development plans if financing is not obtained.
• Potential for substantial dilution to existing stockholders if equity financing is pursued.

Key Dates

Recommendation

The company's severe financial distress, including substantial net losses, a working capital deficit, and a going concern warning, coupled with an absolute reliance on unconfirmed future financing, presents a high-risk investment profile. While the clarification of intellectual property is a positive development, it does not outweigh the immediate financial precariousness. Investors should consider selling their holdings given the significant uncertainty of the company's survival and future prospects.

Keywords

Quantum Genesis AI Corp, Form 10-Q/A, Amendment, Intellectual Property, Asset Purchase Agreement, Patent Application, Enzyme Design, Ibuprofen Synthesis, Going Concern, Net Loss, Operating Expenses, Debt Settlement, Financing